The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study
Open accessAbstract
Background Identification of effective treatments in severe cases of COVID-19 requiring mechanical ventilation represents an unmet medical need. Our aim was to determine whether the administration of adipose-tissue derived mesenchymal stromal cells (AT-MSC) is safe and potentially useful in these patients. Methods Thirteen COVID-19 adult patients under invasive mechanical ventilation who had received previous antiviral and/or anti-inflammatory treatments (including steroids, lopinavir/ritonavir, hydroxychloroquine and/or tocilizumab, among others) were treated with allogeneic AT-MSC. Ten patients received two doses, with the second dose administered a median of 3 days (interquartile range-IQR- 1 day) after the first one. Two patients received a single dose and another patient received 3 doses. Median number of cells per dose was 0.98 × 10 6 (IQR 0.50 × 10 6 ) AT-MSC/kg of recipient's body weight. Potential adverse effects related to cell infusion and clinical outcome were assessed. Additional parameters analyzed included changes in imaging, analytical and inflammatory parameters. Findings First dose of AT-MSC was administered at a median of 7 days (IQR 12 days) after mechanical ventilation. No adverse events were related to cell therapy. With a median follow-up of 16 days (IQR 9 days) after the first dose, clinical improvement was observed in nine patients (70%). Seven patients were extubated and discharged from ICU while four patients remained intubated (two with an improvement in their ventilatory and radiological parameters and two in stable condition). Two patients died (one due to massive gastrointestinal bleeding unrelated to MSC therapy). Treatment with AT-MSC was followed by a decrease in inflammatory parameters (reduction in C-reactive protein, IL-6, ferritin, LDH and d-dimer) as well as an increase in lymphocytes, particularly in those patients with clinical improvement. Interpretation Treatment with intravenous administration of AT-MSC in 13 severe COVID-19 pneumonia under mechanical ventilation in a small case series did not induce significant adverse events and was followed by clinical and biological improvement in most subjects. Funding None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Wynants, L., Van Calster, B., Bonten, M. M., Collins, G. S., Debray, T. P., De Vos, M., Haller, M. C., Heinze, G., Moons, K. G., Riley, R. D., et al. (2020) · doi:10.1101/2020.03.24.20041020 · Cited by 3,070
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654
Du, R.-H., Liang, L.-R., Yang, C.-Q., Wang, W., Cao, T.-Z., Li, M., Guo, G.-Y., Du, J., Zheng, C.-L., Zhu, Q., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00524-2020 · Cited by 1,452
Cited by
Mazini, L., Ezzoubi, M., & Malka, G. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02006-w · Cited by 267
Adipose-derived stem cells secretome and its potential application in “stem cell-free therapy”
Trzyna, A., & Banaś-Ząbczyk, A. (2021) · Biomolecules · doi:10.3390/biom11060878 · Cited by 201
Metadata
- Authors
- Sánchez-Guijo, F., García-Arranz, M., López-Parra, M., Monedero, P., Mata-Martínez, C., Santos, A., Sagredo, V., Álvarez-Avello, J.-M., Guerrero, J. E., Pérez-Calvo, C., Sánchez-Hernández, M.-V., Del-Pozo, J. L., Andreu, E. J., Fernández-Santos, M.-E., Soria-Juan, B., Hernández-Blasco, L. M., Andreu, E., Sempere, J. M., Zapata, A. G., Moraleda, J. M., Soria, B., Fernández-Avilés, F., García-Olmo, D., & Prósper, F.
- Venue
- EClinicalMedicine
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 25
- Pages
- 100454
- ISSN
- 2589-5370 (ISSN-L)
- OpenAlex
- W3041428009
- Cited by
- 180
- References
- 8
- FWCI
- 16.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. https://app.cochat.ai/papers/10.1016/j.eclinm.2020.100454
- The paper
- Sánchez-Guijo, F., García-Arranz, M., López-Parra, M., Monedero, P., Mata-Martínez, C., Santos, A., Sagredo, V., Álvarez-Avello, J.-M., Guerrero, J. E., Pérez-Calvo, C., Sánchez-Hernández, M.-V., Del-Pozo, J. L., Andreu, E. J., Fernández-Santos, M.-E., Soria-Juan, B., Hernández-Blasco, L. M., Andreu, E., Sempere, J. M., Zapata, A. G., . . . Prósper, F. (2020). Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2020.100454
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.